The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Animals Antineoplastic Agents / administration & dosage Cell Proliferation / drug effects Drug Synergism Humans Immunotherapy Inflammation / chemically induced Lung Neoplasms / drug therapy Mice Phosphorylation / drug effects Piperazines / administration & dosage Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors Pyridines / administration & dosage Pyrimidines / administration & dosage Signal Transduction / drug effects Treatment Outcome Tumor Microenvironment / drug effects

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
11 2019

Historique:

received: 29 03 2019

accepted: 18 09 2019

pubmed: 2 11 2019

medline: 14 4 2020

entrez: 1 11 2019

Statut: ppublish

Résumé

KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours

Identifiants

DOI: 10.1038/s41586-019-1694-1 PMID: 31666701

pubmed: 31666701

doi: 10.1038/s41586-019-1694-1

pii: 10.1038/s41586-019-1694-1

doi:

Substances chimiques

Antineoplastic Agents 0

KRAS protein, human 0

Piperazines 0

Pyridines 0

Pyrimidines 0

sotorasib 2B2VM6UC8G

Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

Pagination

217-223

Subventions

Organisme : NIH HHS

ID : S10 OD021832

Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Barbacid, M. ras genes. Annu. Rev. Biochem. 56, 779–827 (1987).

doi: 10.1146/annurev.bi.56.070187.004023

Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17–33 (2017).

doi: 10.1016/j.cell.2017.06.009

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).

doi: 10.1038/nature12796

Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316–329 (2016).

doi: 10.1158/2159-8290.CD-15-1105

Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578–589 (2018).

doi: 10.1016/j.cell.2018.01.006

Pai, E. F. et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 341, 209–214 (1989).

doi: 10.1038/341209a0

Milburn, M. V. et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247, 939–945 (1990).

doi: 10.1126/science.2406906

Cully, M. & Downward, J. SnapShot: Ras signaling. Cell 133, 1292–1292.e1 (2008).

doi: 10.1016/j.cell.2008.06.020

Vetter, I. R. & Wittinghofer, A. The guanine nucleotide-binding switch in three dimensions. Science 294, 1299–1304 (2001).

doi: 10.1126/science.1062023

Scheffzek, K. et al. The Ras–RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333–338 (1997).

doi: 10.1126/science.277.5324.333

Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A. & Eckhardt, S. G. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J. 15, 110–113 (2009).

doi: 10.1097/PPO.0b013e31819e3202

Welsh, S. J. & Corrie, P. G. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther. Adv. Med. Oncol. 7, 122–136 (2015).

doi: 10.1177/1758834014566428

Fakih, M. & Vincent, M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr. Oncol. 17, S18–S30 (2010).

pubmed: 20680104 pmcid: 20680104

AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017).

doi: 10.1158/2159-8290.CD-17-0151

Hansen, R. et al. The reactivity-driven biochemical mechanism of covalent KRAS

doi: 10.1038/s41594-018-0061-5

clinicaltrials.gov. A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation https://clinicaltrials.gov/ct2/show/NCT03600883 (2018).

Gentile, D. R. et al. Ras binder induces a modified switch-II Pocket in GTP and GDP states. Cell Chem. Biol. 24, 1455–1466 (2017).

doi: 10.1016/j.chembiol.2017.08.025

Schwartz, P. A. et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc. Natl Acad. Sci. USA 111, 173–178 (2014).

doi: 10.1073/pnas.1313733111

Cee, V. J. et al. Systematic study of the glutathione (GSH) reactivity of N-arylacrylamides: 1. Effects of aryl substitution. J. Med. Chem. 58, 9171–9178 (2015).

doi: 10.1021/acs.jmedchem.5b01018

Jackson, P. A., Widen, J. C., Harki, D. A. & Brummond, K. M. Covalent modifiers: a chemical perspective on the reactivity of α,β-unsaturated carbonyls with thiols via hetero-Michael addition reactions. J. Med. Chem. 60, 839–885 (2017).

doi: 10.1021/acs.jmedchem.6b00788

Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol. 20, 1064–1073 (2018).

doi: 10.1038/s41556-018-0169-1

Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30–39 (2015).

doi: 10.1056/NEJMoa1412690

Saiki, A. Y. et al. MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways. Oncotarget 5, 2030–2043 (2014).

doi: 10.18632/oncotarget.1918

Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609–621 (2016).

doi: 10.1016/j.immuni.2016.01.024

Selby, M. J. et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS ONE 11, e0161779 (2016).

doi: 10.1371/journal.pone.0161779

Mosely, S. I. et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol. Res. 5, 29–41 (2017).

doi: 10.1158/2326-6066.CIR-16-0114

Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723 (2017).

doi: 10.1016/j.ccell.2017.04.003

Gao, Q. et al. Cancer-cell-secreted CXCL11 promoted CD8

doi: 10.1186/s40425-019-0511-6

Lee, J. W. et al. The combination of MEK inhibitor with immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras/p53-driven lung cancer. Journal Thorac. Oncol. 14, 1046–1060 (2019).

doi: 10.1016/j.jtho.2019.02.004

Liu, L. et al. The BRAF and MEK inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 21, 1639–1651 (2015).

doi: 10.1158/1078-0432.CCR-14-2339

Kordiak, J. et al. Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate. J. Cancer Res. Clin. Oncol. 145, 241–251 (2019).

doi: 10.1007/s00432-018-2779-1

Lamy, A. et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod. Pathol. 24, 1090–1100 (2011).

doi: 10.1038/modpathol.2011.60

Richman, S. D. et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal. Cell. Pathol. 34, 61–66 (2011).

doi: 10.1155/2011/393521